<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">San-Miguel, J.F.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Stadtmauer, E.A.</style></author><author><style face="normal" font="default" size="100%">Rajkumar, S.V.</style></author><author><style face="normal" font="default" size="100%">Siegel, D.</style></author><author><style face="normal" font="default" size="100%">Bravo, M.-L.</style></author><author><style face="normal" font="default" size="100%">Olesnyckyj, M.</style></author><author><style face="normal" font="default" size="100%">Knight, R.D.</style></author><author><style face="normal" font="default" size="100%">Zeldis, J.B.</style></author><author><style face="normal" font="default" size="100%">Harousseau, J.-L.</style></author><author><style face="normal" font="default" size="100%">Weber, D.M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Lymphoma, Myeloma and Leukemia</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Granulocyte colony-stimulating factor</style></keyword><keyword><style  face="normal" font="default" size="100%">MM-009</style></keyword><keyword><style  face="normal" font="default" size="100%">MM-010</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutropenia</style></keyword><keyword><style  face="normal" font="default" size="100%">Partial response</style></keyword><keyword><style  face="normal" font="default" size="100%">Thrombocytopenia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953716823&amp;doi=10.3816%2fCLML.2010.n.120&amp;partnerID=40&amp;md5=97faef542d8cd3674c3499f75fbf5566</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">38 - 43</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethasone alone. In both trials the treatment was continued until disease progression or unacceptable toxicity. We conducted a subanalysis to determine if continuing therapy after achieving ≥ partial response (PR) improved survival. Patients and Methods: Data were collected on 212 patients who were treated with lenalidomide plus dexamethasone and achieved ≥ PR. Kaplan-Meier survival estimates were compared between patients on continued treatment versus patients discontinuing therapy because of adverse events, withdrawal of consent, or other reasons. Time-dependent multivariate regression analyses were used to determine the benefit of continuing treatment with lenalidomide. Results: A total of 174 patients received continued treatment until disease progression or death, and 38 patients discontinued therapy without progression. There was a trend toward longer median OS in patients who continued therapy (50.9 months vs. 35.0 months; P = .0594). When controlling for the number of previous antimyeloma therapies, β2-microglobulin levels, and Durie-Salmon stage (which adversely affected survival in these patients), continued lenalidomide treatment (HR, 0.137; 95% CI, 0.045-0.417; P = .0005) or each additional cycle of lenalidomide (HR, 0.921; 95% CI, 0.886-0.957; P &amp;lt; .0001) were both associated with longer survival. Conclusion: Continued lenalidomide treatment until disease progression after achievement of ≥ PR is associated with a significant survival advantage when controlling for patient characteristics. These findings should be confirmed in a prospectively designed trial. © 2011 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :43Export Date: 21 February 2017</style></notes></record></records></xml>